Monopar Historical Cash Flow
| MNPR Stock | USD 20.70 1.25 6.43% |
Analysis of Monopar Therapeutics cash flow over time is an excellent tool to project Monopar Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change To Netincome of 1.3 M or Change To Liabilities of 234.9 K as it is a great indicator of Monopar Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Monopar Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Monopar Therapeutics is a good buy for the upcoming year.
Monopar |
About Monopar Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Monopar balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Monopar's non-liquid assets can be easily converted into cash.
Monopar Therapeutics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Most accounts from Monopar Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Monopar Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.At this time, Monopar Therapeutics' End Period Cash Flow is relatively stable compared to the past year. As of 11/29/2024, Begin Period Cash Flow is likely to grow to about 11.1 M, though Other Cashflows From Financing Activities is likely to grow to (44.6 K).
| 2023 | 2024 (projected) | Stock Based Compensation | 1.9M | 1.3M | Net Borrowings | 110.2K | 97.9K |
Monopar Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Monopar Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Monopar Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 6.3M | 3.5M | 3.6M | (12.1M) | (920.1K) | (874.1K) | |
| Other Cashflows From Financing Activities | (874.8K) | (115.6K) | (45.8K) | (76.5K) | (47.0K) | (44.6K) | |
| Total Cash From Operating Activities | (3.0M) | (4.7M) | (7.3M) | (7.2M) | (7.9M) | (7.5M) | |
| Change To Operating Activities | (69.6K) | (47.5K) | (3.8K) | (86.2K) | (77.6K) | (81.5K) | |
| Net Income | (4.2M) | (6.3M) | (9.1M) | (10.5M) | (8.4M) | (8.8M) | |
| Total Cash From Financing Activities | 9.3M | 8.2M | 10.9M | 32.9K | 2.0M | 1.9M | |
| End Period Cash Flow | 13.2M | 16.7M | 20.3M | 8.2M | 7.3M | 10.8M | |
| Change To Netincome | 529.3K | 1.0M | 1.2M | 1.5M | 1.3M | 1.3M | |
| Change To Liabilities | 87.7K | 243.5K | 447.6K | 404.0K | 464.6K | 234.9K | |
| Free Cash Flow | (3.0M) | (4.7M) | (7.3M) | (7.2M) | (7.9M) | (7.5M) | |
| Change In Working Capital | 196.0K | 443.8K | 317.8K | 1.6M | (1.4M) | (1.3M) | |
| Begin Period Cash Flow | 6.9M | 13.2M | 16.7M | 20.3M | 8.2M | 11.1M | |
| Stock Based Compensation | 1.0M | 1.3M | 1.5M | 1.6M | 1.9M | 1.3M | |
| Other Non Cash Items | 767.6K | (122.4K) | 1.1M | 163.0K | 1.9M | 2.2M | |
| Issuance Of Capital Stock | 10.2M | 8.2M | 10.9M | 109.3K | 1.8M | 1.8M |
Pair Trading with Monopar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Monopar Stock
| 0.65 | VTRS | Viatris | PairCorr |
| 0.74 | ESPR | Esperion Therapeutics | PairCorr |
| 0.66 | EWTX | Edgewise Therapeutics | PairCorr |
Moving against Monopar Stock
| 0.89 | TAK | Takeda Pharmaceutical | PairCorr |
| 0.85 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.84 | RDY | Dr Reddys Laboratories | PairCorr |
| 0.8 | LLY | Eli Lilly Sell-off Trend | PairCorr |
| 0.78 | ZTS | Zoetis Inc | PairCorr |
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.